Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Gemcitabine, Capecitabine, and Erlotinib Together in Advanced Pancreatic Cancers

NCT00885066 is registered in ClinicalTrials.gov with Centre Antoine Lacassagne as lead sponsor.

NCT NCT00885066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00885066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Gemcitabine, Capecitabine, and Erlotinib Together in Advanced Pancreatic Cancers
Lead sponsor
Centre Antoine Lacassagne
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2008
Completion date
October 31, 2009
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer